EUCTR2012-003067-22-NLActive, not recruitingNot Applicable
Pneumonia treated with rifampicine attenuates inflammation - PRIsTINe
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- MC
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1.Patient aged 18 years or above
- •2.Community acquired pneumonia with CURB65 score = 2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
Exclusion Criteria
- •Known allergy to rifampicin or anaemia or thrombopenia as side effect of rifampicin in medical history
- •Medication induced hepatitis or acute liver failure
- •????Renal failure with creatinin clearance < 25 ml/min
- •Use of voriconazol or protease inhibitors
- •health care associated pneumonia
- •Female patients who are pregnant
- •Lung transplant recipients
Investigators
Similar Trials
Completed
Phase 4
Pneumonia treated with rifampicine attenuates inflammatio1000401810024970respiratory tract infectionpneumoniaNL-OMON39089eids Universitair Medisch Centrum40
Completed
Not Applicable
Rifampicine vermindert de ontstekingsreactie bij patienten met een (matig) ernstige longontsteking.Community Acquired PneumoniaRifampicinLipoteichoid AcidPneumolysininflammatory responsclinical outcome prognosispneumoniaEmergency medicinehospitalSpoedeisende hulpziekenhuisThuis opgelopen longontstekingCURB-65 scorerifampicinelipoteichoidzuurpneumolysineinflammatoire responsprognoseklinische uitkomstpneumonieNL-OMON22991Prof. dr. J.T. van DisselLUMC40
Completed
Not Applicable
A clinical trial to study the effect of Rifampicin in children with bacterial meningitisCTRI/2015/06/005951PGIMER40
Active, not recruiting
Phase 1
CLINICAL TRIAL TO EVALUATE THE EFFICIENCY OF PYRPHENIDONE FOR THE REDUCTION OF PULMONARY INFLAMMATION IN PATIENTS WITH SILICOSIS AND PROGRESSIVE MASSIVE FIBROSIS.progressive massive fibrosisMedDRA version: 20.0Level: PTClassification code 10040678Term: SilicosisSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 21.1Level: PTClassification code 10036805Term: Progressive massive fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-002701-94-ESFundación para la Gestión de la Investigación Biomédica de Cádiz18
Active, not recruiting
Not Applicable
Effects of rifampicin on the pharmacokinetics and pharmacodynamics of sublingual and intravenous buprenorphineEUCTR2012-002871-32-FITurku University hospital